Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort

Pieter J. Vlaar, Charanjit Rihal, Mandeep Singh, Ryan Lennon, Henry H. Ting, John F. Bresnahan, David Holmes

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: The objective of this study is to investigate the clinical outcome of a large cohort of patients with ST-segment elevation myocardial infarction (STEMI) treated with drug-eluting stents (DES) compared to bare metal stents (BMS). Background: Several randomized controlled trials have demonstrated that PCI with the routine use of DES is safe and effective in patients with STEMI. However as randomized trials have strict inclusion criteria, further studies in unselected patient populations are needed. Methods: We performed a retrospective cohort analysis of the Mayo Clinic PCI database. A total of 552 consecutive STEMI patients who underwent a DES implantation between May 2003 and April 2006 were included in the study and compared to 557 who had BMS for STEMI earlier. No specific patient subsets were excluded. Results: Procedural success was achieved in 532 patients (96%). During initial hospitalization, 16 patients (2.9%) died and 8 (1.5%) suffered from a recurrent myocardial infarction. The median follow-up was 23 months (IQR: 13-27 months). At 12 months post discharge, the rate of target lesion revascularization and death were 2.9% and 3.7%, respectively, and survival free of major adverse cardiac events (MACE) was 90.9%. These rates were similar to or lower than those of patients treated for STEMI with BMS prior to the availability of DES. Conclusion: DES are safe and effective in the treatment of STEMI in an unselected cohort; 90.9% of patients are free of MACE at 12 months post discharge.

Original languageEnglish (US)
Pages (from-to)764-769
Number of pages6
JournalCatheterization and Cardiovascular Interventions
Volume71
Issue number6
DOIs
StatePublished - May 1 2008

Fingerprint

Drug-Eluting Stents
Safety
Myocardial Infarction
Stents
Metals
ST Elevation Myocardial Infarction
Hospitalization
Cohort Studies
Randomized Controlled Trials
Databases
Survival

Keywords

  • ACS, acute coronary syndrome
  • PCI, percutaneous coronary intervention
  • RSTN, restenosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort. / Vlaar, Pieter J.; Rihal, Charanjit; Singh, Mandeep; Lennon, Ryan; Ting, Henry H.; Bresnahan, John F.; Holmes, David.

In: Catheterization and Cardiovascular Interventions, Vol. 71, No. 6, 01.05.2008, p. 764-769.

Research output: Contribution to journalArticle

Vlaar, Pieter J. ; Rihal, Charanjit ; Singh, Mandeep ; Lennon, Ryan ; Ting, Henry H. ; Bresnahan, John F. ; Holmes, David. / Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort. In: Catheterization and Cardiovascular Interventions. 2008 ; Vol. 71, No. 6. pp. 764-769.
@article{bc0f22f96b0f4d1888ee513c8d93b8f2,
title = "Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort",
abstract = "Objective: The objective of this study is to investigate the clinical outcome of a large cohort of patients with ST-segment elevation myocardial infarction (STEMI) treated with drug-eluting stents (DES) compared to bare metal stents (BMS). Background: Several randomized controlled trials have demonstrated that PCI with the routine use of DES is safe and effective in patients with STEMI. However as randomized trials have strict inclusion criteria, further studies in unselected patient populations are needed. Methods: We performed a retrospective cohort analysis of the Mayo Clinic PCI database. A total of 552 consecutive STEMI patients who underwent a DES implantation between May 2003 and April 2006 were included in the study and compared to 557 who had BMS for STEMI earlier. No specific patient subsets were excluded. Results: Procedural success was achieved in 532 patients (96{\%}). During initial hospitalization, 16 patients (2.9{\%}) died and 8 (1.5{\%}) suffered from a recurrent myocardial infarction. The median follow-up was 23 months (IQR: 13-27 months). At 12 months post discharge, the rate of target lesion revascularization and death were 2.9{\%} and 3.7{\%}, respectively, and survival free of major adverse cardiac events (MACE) was 90.9{\%}. These rates were similar to or lower than those of patients treated for STEMI with BMS prior to the availability of DES. Conclusion: DES are safe and effective in the treatment of STEMI in an unselected cohort; 90.9{\%} of patients are free of MACE at 12 months post discharge.",
keywords = "ACS, acute coronary syndrome, PCI, percutaneous coronary intervention, RSTN, restenosis",
author = "Vlaar, {Pieter J.} and Charanjit Rihal and Mandeep Singh and Ryan Lennon and Ting, {Henry H.} and Bresnahan, {John F.} and David Holmes",
year = "2008",
month = "5",
day = "1",
doi = "10.1002/ccd.21479",
language = "English (US)",
volume = "71",
pages = "764--769",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort

AU - Vlaar, Pieter J.

AU - Rihal, Charanjit

AU - Singh, Mandeep

AU - Lennon, Ryan

AU - Ting, Henry H.

AU - Bresnahan, John F.

AU - Holmes, David

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Objective: The objective of this study is to investigate the clinical outcome of a large cohort of patients with ST-segment elevation myocardial infarction (STEMI) treated with drug-eluting stents (DES) compared to bare metal stents (BMS). Background: Several randomized controlled trials have demonstrated that PCI with the routine use of DES is safe and effective in patients with STEMI. However as randomized trials have strict inclusion criteria, further studies in unselected patient populations are needed. Methods: We performed a retrospective cohort analysis of the Mayo Clinic PCI database. A total of 552 consecutive STEMI patients who underwent a DES implantation between May 2003 and April 2006 were included in the study and compared to 557 who had BMS for STEMI earlier. No specific patient subsets were excluded. Results: Procedural success was achieved in 532 patients (96%). During initial hospitalization, 16 patients (2.9%) died and 8 (1.5%) suffered from a recurrent myocardial infarction. The median follow-up was 23 months (IQR: 13-27 months). At 12 months post discharge, the rate of target lesion revascularization and death were 2.9% and 3.7%, respectively, and survival free of major adverse cardiac events (MACE) was 90.9%. These rates were similar to or lower than those of patients treated for STEMI with BMS prior to the availability of DES. Conclusion: DES are safe and effective in the treatment of STEMI in an unselected cohort; 90.9% of patients are free of MACE at 12 months post discharge.

AB - Objective: The objective of this study is to investigate the clinical outcome of a large cohort of patients with ST-segment elevation myocardial infarction (STEMI) treated with drug-eluting stents (DES) compared to bare metal stents (BMS). Background: Several randomized controlled trials have demonstrated that PCI with the routine use of DES is safe and effective in patients with STEMI. However as randomized trials have strict inclusion criteria, further studies in unselected patient populations are needed. Methods: We performed a retrospective cohort analysis of the Mayo Clinic PCI database. A total of 552 consecutive STEMI patients who underwent a DES implantation between May 2003 and April 2006 were included in the study and compared to 557 who had BMS for STEMI earlier. No specific patient subsets were excluded. Results: Procedural success was achieved in 532 patients (96%). During initial hospitalization, 16 patients (2.9%) died and 8 (1.5%) suffered from a recurrent myocardial infarction. The median follow-up was 23 months (IQR: 13-27 months). At 12 months post discharge, the rate of target lesion revascularization and death were 2.9% and 3.7%, respectively, and survival free of major adverse cardiac events (MACE) was 90.9%. These rates were similar to or lower than those of patients treated for STEMI with BMS prior to the availability of DES. Conclusion: DES are safe and effective in the treatment of STEMI in an unselected cohort; 90.9% of patients are free of MACE at 12 months post discharge.

KW - ACS, acute coronary syndrome

KW - PCI, percutaneous coronary intervention

KW - RSTN, restenosis

UR - http://www.scopus.com/inward/record.url?scp=43249130898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249130898&partnerID=8YFLogxK

U2 - 10.1002/ccd.21479

DO - 10.1002/ccd.21479

M3 - Article

C2 - 18412074

AN - SCOPUS:43249130898

VL - 71

SP - 764

EP - 769

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 6

ER -